ClinicalTrials.gg
Not yet recruitingNCT07436234Updated Feb 27, 2026

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis

A Phase 2 interventional study of AK139 and AK139 in Seasonal Allergic Rhinitis, sponsored by Akeso. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Rhinitis, Allergic, Seasonal with a site in China — 12 open to participants now, 14 under way, 8 of them phase 3. Rhinitis, Allergic, Seasonal · China.

Planned enrollment
21st of 27
111 · median 160
Started
2026
with 5 others
Phase 2
12 of 27
5 open now
Primary completion
2026-09
later than 6 of 13 live
Registered
22nd of 27
by date
Lead sponsor
1 of 27
Akeso

Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, this one is the 21st largest by planned enrollment, is one of 6 that started in 2026, is one of 12 in phase 2, reaches primary completion later than 6 of the 13 other live ones, and was the 22nd registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

12 of the 27 studies in Rhinitis, Allergic, Seasonal with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Rhinitis, Allergic, Seasonal with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe SAR

Read the detailed description

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe SAR. Participants will be randomized to receive AK139 regimen or placebo subcutaneous injection and followed up to week 12

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18-65.
  2. Able to understand the study and voluntarily sign the ICF;
  3. Diagnosed SAR according to the Criteria stated in the Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition), with or without allergic conjunctivitis, and have SAR history at least two years;
  4. Have immunoglobulin E (Ig E)-mediated to at least one pollen allergen in the current environment;
  5. The SAR symptoms of participants remained inadequately control ledafter nasal spray and/or other SAR medications treatment throughout the previous same pollen season;
  6. Adequate pollen exposure during the pollen season.
  7. The SAR symptoms scores of the participants meet the requirements of the protocol at screening and baseline.
  8. During the screening/run-in period, participants must complete at least 80% of the assessments in the diary card;
  9. The participants agree to use highly effective methods from the moment of signing of the ICF to 3 months after the last dose of the product.

Exclusion criteria

Exclusion Criteria:

  1. Type of rhinitis other than allergic rhinitis within 2 weeks before screening;
  2. Allergic to any component of the drug or intolerant to basis treatment..
  3. Concomitant or associated nasal diseases/conditions that, as determined by investigators, may affect the severity of the disease and the evaluation of therapeutic effects.
  4. Ongoing use of prohibited treatments. detailed in the protocol have to be adhered to.
  5. Other reasons the investigators believes that the participants is not suitable to enrolled in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
111 participants (estimated)

Study arms

  • Experimental
    AK139 regimen 1

    Drug: AK139

  • Experimental
    AK139 regimen 2

    Drug: AK139

  • Experimental
    Placebo

    Drug: Placebo

Interventions

  • DrugAK139

    AK139 regimen 1- subcutaneous injection.

  • DrugAK139

    AK139 regimen 2- subcutaneous injection

  • DrugPlacebo

    Placebo-subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in daily reflective total nasal symptom scores (rTNSS) over 2 weeks of treatment

    Time frame: Up to week 2

  2. Incidence of adverse events (AEs)

    Time frame: Up to week 12

Secondary outcomes

  1. Mean change from baseline in daily rTNSS over 2 and 4 weeks of treatment

    Time frame: Up to week 4

  2. Mean change from baseline in the daily AM and PM reflective total nasal symptom score (AM and PM rTNSS) over 2 and 4 weeks of treatment

    Time frame: Up to week 4

  3. Serum AK139 concentration

    Time frame: Up to week 12

  4. Number of participants with detectable anti-drug antibodies (ADA) and neutralizing antibodies (Nab) after treatment.

    Time frame: Up to week 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Sep 2026, 6 months later.

Of 24 phase 2 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's planned 6 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 27, 2026
StartEst.
Mar 2, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
May 13, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07436234
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 2, 2026 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
May 13, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Guoqin Wang
Contact
global.trials@akesobio.com
+86 (0760) 8987 3999

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK139

Start the discussion